- Study successfully meets its primary effectiveness objectives and its secondary safety and tolerability objectives.
- Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcyclopropenone (DPCP), a topical immunomodulator that works by initiating a T-cell response.
- Currently, there are no prescription drugs approved by the FDA for the treatment of common warts.
PR Newswire
MARLBOROUGH, Mass., May 18, 2018